EligibleTrials

Clinical trials recruiting for Dermatomyositis

10
Recruiting trials
20
US states with sites
7
Countries
30%
Accept healthy volunteers

Phase breakdown

Phase 1 4Phase 2 2Not applicable 6

Drugs and treatments being studied

InterventionTrials
CAR T cell1
CD19 targeted CAR-T cells1
Cabozantinib1
Fluoropyrimidine1
Ipilimumab1
KYV-1011
Nivolumab1
Platinum Compound1
Platinum Doublet1
anti-CD19 CAR T cell therapy1
anti-CD19/BCMA-UCAR-T cells1

Where trials are recruiting (top US states)

StateRecruiting trials
Connecticut2
Alabama1
California1
Colorado1
District of Columbia1
Georgia1
Illinois1
Kansas1
Kentucky1
Maryland1
Massachusetts1
Michigan1

Top cities

New Haven, Connecticut 2Atlanta, Georgia 1Baltimore, Maryland 1Bethesda, Maryland 1Birmingham, Alabama 1Boston, Massachusetts 1Chicago, Illinois 1City of Saint Peters, Missouri 1Columbus, Ohio 1Creve Coeur, Missouri 1

Self-screener

Recruiting trials

Related conditions

Trials recruiting for Dermatomyositis often also study these conditions. Each links to its own recruiting-trial list.

Lupus 332Rheumatoid arthritis 314Systemic lupus erythematosus 119Systemic Sclerosis 27Psoriasis 233Polymyositis 3Multiple sclerosis 445Systemic Scleroderma 3Sjogren's Syndrome 25Psoriatic arthritis 45

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for Dermatomyositis trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.